Medindia

X

Senhwa Biosciences Files New Patent Applications for Use of CX-5461 in Combination with PARP inhibitors, PI3K and Immunotherapeutic Agents

Tuesday, November 15, 2016 Drug News J E 4
Advertisement

TAIPEI, Taiwan, Nov. 14, 2016 /PRNewswire-iReach/ --  Senhwa Biosciences Inc. has filed new patent applications covering the use of CX-5461 in combination with PARP inhibitors, PI3K, and immunotherapeutic agents. These new patent application are based on preclinical discoveries in synergistic effects in animal PDX models and cell line studies.

CX-5461 is a small molecule that targets synthetic lethal vulnerability in cancer cells. In the patient derived xenograft (PDX) studies, 100% of the animals administered with CX-5461 and PARP inhibitor demonstrated complete tumor regression. The combination treatment delayed tumor growth from just 12 days to over 100 days. In addition, patient derived xenografts administered with CX-5461 showed significant increase in several important chemokines with CX-5461 exhibiting a dose dependent enhancement of the cytotoxic immune responses.  

"These new patent applications, if granted, will add value to the patent estate surrounding CX-5461," stated Dr. Tai-Sen Soong, Senhwa's CEO. "The expanded patent life could open up new potential strategic options for the future development of CX-5461 in multiple indications."

To date, Senhwa Biosciences owns 108 patents or pending patent applications in total; 90 have been granted and 18 are pending for approval. 

About CX-5461 and DNA repair

CX-5461 is a potent G-quadruplex stabilizer that trigger replication and transcription associated DNA damage in cancer cells with defective DNA damage repair due to BRCA1/2 mutation or HR deficiency. Normal cells have all of their DNA repair mechanisms intact allowing them to survive. By stabilizing G-quadruplex, CX-5461 selectively kill tumors through the concept of synthetic lethality.

About Senhwa Biosciences

Senhwa Biosciences identifies and develops innovative therapies that have the potential to fundamentally change the way patients are treated. Our central philosophy is to unearth validated targets or therapies that could significantly improve treatment, but have not yet been properly exploited. As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through clinical Proof-of-Concept.

Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global Investigators and service providers. Clinical trials are ongoing or planned for Australia and the US, and service providers work from their bases in North America, Asia, Australia and Europe.For more information on Senhwa and its programs, please visit www.senhwabio.com.

Media Contact: Gwen Chang, Senhwa Biosciences, +886289131956#112, gwenchang@senhwabio.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Senhwa Biosciences

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VIIHEALTH subsidiary Argolife Launches MCM Builder...
S
New Evidence-Based Guideline on HER2 Testing for P...